2017
DOI: 10.1016/j.eururo.2017.03.037
|View full text |Cite
|
Sign up to set email alerts
|

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
121
0
10

Year Published

2017
2017
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 208 publications
(138 citation statements)
references
References 15 publications
6
121
0
10
Order By: Relevance
“…In the context of all patients randomized to receive nivolumab in the trial, this translates to an efficacy benefit of treatment beyond progression in 1.3% (3 of 240). 14,15 In CheckMate 141, the ORR before RECISTdefined progression was higher in the TBP group than It is important to note that although interesting, the small patient numbers in our study preclude us from drawing definitive conclusions about patient characteristics predictive of clinical benefit from treatment with nivolumab beyond RECIST-defined progression. 2 In a landmark analysis, the median OS starting week 6 after RECISTdefined progression was 8.4 months for the TBP group and 3.8 months for the NTBP group.…”
Section: Discussionmentioning
confidence: 62%
“…In the context of all patients randomized to receive nivolumab in the trial, this translates to an efficacy benefit of treatment beyond progression in 1.3% (3 of 240). 14,15 In CheckMate 141, the ORR before RECISTdefined progression was higher in the TBP group than It is important to note that although interesting, the small patient numbers in our study preclude us from drawing definitive conclusions about patient characteristics predictive of clinical benefit from treatment with nivolumab beyond RECIST-defined progression. 2 In a landmark analysis, the median OS starting week 6 after RECISTdefined progression was 8.4 months for the TBP group and 3.8 months for the NTBP group.…”
Section: Discussionmentioning
confidence: 62%
“…Although these systemic agents have been replaced by molecular, targeted therapies during the last years, the immunogenic potential of RCC remains an exciting avenue for future study. Immunotherapy with antibodies against the programmed cell death protein 1 (PD-1) or its ligand 1 (PD-L1) have demonstrated excellent preliminary results (48)(49)(50). Interestingly, SBRT might also be applied to enhance immunogenic the anti-tumor response via the abscopal effect: clinical studies have described regression of non-irradiated distant lesions following SBRT to an RCC metastasis (51)(52)(53).…”
Section: Toxicitymentioning
confidence: 99%
“…For example, in various Checkmate trials, the criteria to treat beyond progression was tolerability and apparent clinical benefit, assessed at the discretion of the investigator [14, 15]. The presumption is that only those with favorable clinical characteristics at progression would merit continuing the same treatment instead of changing to another.…”
Section: Discussionmentioning
confidence: 99%